Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Monopar Therapeutics Inc MNPR

Healthcare Biotechnology
Monopar Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for cancer patients. The Company is building a drug candidate pipeline through in-house development as well as the licensing and acquisition of therapeutics in late preclinical and in clinical development stages. The Company has several compounds in development, which include MNPR-101-Zr... see more

Recent & Breaking News (NDAQ:MNPR)

Monopar Therapeutics Reports First Quarter 2024 Financial Results and Strategic Focus on its Radiopharma Pipeline

GlobeNewswire May 9, 2024

Monopar Announces Radiopharma Presentation Selected for Society of Nuclear Medicine and Molecular Imaging 2024 Annual Meeting

GlobeNewswire April 18, 2024

Monopar Announces Filing of Patent Protecting MNPR-101 Radiopharma Optimization Findings

GlobeNewswire April 16, 2024

Monopar Initiates Radiopharma Phase 1 Clinical Trial for MNPR-101-Zr in Advanced Cancer Patients

GlobeNewswire April 10, 2024

Monopar Reports Fourth Quarter and Full-Year 2023 Financial Results and Recent Developments

GlobeNewswire March 28, 2024

Monopar Announces Positive Preclinical Therapeutic Isotope Data for its MNPR-101 Radiopharma Program

GlobeNewswire March 5, 2024

Monopar Provides Update on MNPR-101-Zr Radiopharma Clinical Trial

GlobeNewswire February 27, 2024

Monopar Announces Promising Preclinical Data for its MNPR-101 Radiopharma Program Targeting Advanced Cancers

GlobeNewswire February 22, 2024

Monopar Receives Clearance to Proceed with First-in-Human Phase 1 Trial of Novel Radiopharmaceutical MNPR-101-Zr in Advanced Cancers

GlobeNewswire February 20, 2024

Monopar Therapeutics Reports Third Quarter 2023 Financial Results and Recent Developments

GlobeNewswire November 9, 2023

Monopar Presents Data Showing Tumor Reduction Benefit of Camsirubicin from Ongoing Phase 1b at the 2023 Connective Tissue Oncology Society (CTOS) Annual Meeting

GlobeNewswire November 1, 2023

Monopar to Participate in the Roth MKM 2023 Healthcare Opportunities Conference

GlobeNewswire October 10, 2023

Monopar to Participate in the H.C. Wainwright 25th Annual Global Investment Conference

GlobeNewswire September 5, 2023

Monopar Therapeutics Reports Second Quarter 2023 Financial Results and Recent Developments

GlobeNewswire August 10, 2023

Monopar Provides Encouraging Camsirubicin Clinical Data Update

GlobeNewswire August 8, 2023

Monopar Announces MNPR-101 Radiopharma Collaboration Agreement with National University of Singapore

GlobeNewswire July 11, 2023

Monopar to Participate in the Radiopharma Forum by the Lake 2023

GlobeNewswire June 21, 2023

Monopar to Participate in the Maxim Group's Healthcare Virtual Conference

GlobeNewswire June 14, 2023

Monopar Announces Encouraging Camsirubicin Phase 1b Trial Update

GlobeNewswire June 1, 2023

Monopar Therapeutics Reports First Quarter 2023 Financial Results and Recent Developments

GlobeNewswire May 11, 2023